Cefaclor and cefamandole as alternatives to spectinomycin in the treatment of men with uncomplicated gonorrhoea

• Published in: British journal of venereal diseases 1983-10, Vol.59 (5), p.298-301
• Main Authors: Panikabutra, K, Ariyarit, C, Chitwarakorn, A, Saensanoh, C
• Format: Article
• Language: English
• Subjects: Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; Biological and medical sciences; Cefaclor - therapeutic use; Cefamandole - therapeutic use; Cephalexin - analogs & derivatives; Drug Therapy, Combination; Gonorrhea - drug therapy; Humans; Male; Medical sciences; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Neisseria gonorrhoeae - drug effects; Neisseria gonorrhoeae - enzymology; Penicillinase - biosynthesis; Pharmacology. Drug treatments; Probenecid - therapeutic use; Spectinomycin - therapeutic use; Urethritis - drug therapy
• ISSN: 0007-134X; 1368-4973; 1472-3263
• DOI: 10.1136/sti.59.5.298

Between 25 December 1981 and 11 March 1982, 400 men with uncomplicated gonococcal urethritis were randomly assigned to one of four treatment regimens: spectinomycin 2 g intramuscularly (group A); cefamandole 1 g intramuscularly after probenecid 1 g orally (group B); cefaclor 3 g orally with probenecid 1 g orally (group C); and cefaclor 3 g orally (group D). The cure rates were 91 of 92 (98.9%) in group A, 68 of 96 (70.8%) in group B, 88 of 92 (95.8%) in group C, and 86 of 96 (89.6%) in group D. Cefaclor at a dose of 3 g given orally with 1 g probenecid appears to be an effective alternative to spectinomycin 2 g in the treatment of gonorrhoea in areas where strains of penicillinase producing Neisseria gonorrhoeae (PPNG) are prevalent.